SD Biosensor137310.KS

About SD Biosensor

SD Biosensor develops and manufactures in-vitro diagnostic products, spanning rapid antigen and antibody tests, molecular diagnostics, and blood-glucose monitoring systems. The company built global scale as one of the world's largest suppliers of rapid test kits during the COVID-19 pandemic and has since worked to broaden its portfolio into routine immunoassay and point-of-care platforms. It expanded its overseas footprint through acquisitions, including a U.S. diagnostics business that gave it direct channels into developed markets. Revenue comes from selling test kits, analyzers, and consumables to governments, hospitals, distributors, and international health organizations.

The structural question for foreign holders is how a business scaled for pandemic-era demand performs in a normalized diagnostics market. SD Biosensor is heavily export-oriented, so currency movements and procurement cycles at overseas public-health buyers matter more than Korean domestic conditions. Its acquired U.S. operations shift part of the cost base and regulatory exposure into the FDA regime. The company remains founder-led, which concentrates strategic decisions, and demand for its core rapid-test category is episodic, tied to seasonal illness and outbreak-driven purchasing rather than steady consumption.

SD Biosensor was established in 2010 by Cho Young-shik, a diagnostics entrepreneur who had earlier built Standard Diagnostics, a rapid-test maker founded in 1999 that was later sold to a U.S. diagnostics group. The new company carried forward the biosensor and immunoassay know-how from that lineage and grew quietly for a decade before the COVID-19 pandemic transformed it into one of the world's largest rapid-test suppliers. It listed on the KOSPI market in 2021 at the height of testing demand. The company then redeployed its pandemic windfall into acquisitions, most significantly the purchase of Meridian Bioscience, a U.S. diagnostics and life-science firm, completed in 2023 with a Korean private-equity partner.

Revenue follows a platform-and-consumables logic: SD Biosensor places analyzers and readers with hospitals, clinics, and laboratories, then earns recurring sales from the test cartridges, strips, and reagents those instruments consume. Distribution runs through several distinct channels, including government and international-organization tenders, wholesale distributors, pharmacy retail for self-tests, and direct sales in markets where it owns local subsidiaries. The Meridian acquisition added an American commercial network and a raw-materials arm that supplies antigens, antibodies, and enzymes to other test manufacturers, diversifying the company beyond finished kits. Its competitive standing rests on manufacturing scale and cost, fields where it contends with the global diagnostics majors.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on SD Biosensor →